Arai M., Hanada M., Taniguchi H., Nakajima F., Ohmoto H., Inoue T, Naka K., Sawa M. Discovery of HM-279, a potent inhibitor of ALK5 for improving therapeutic efficiency of cancer immunotherapy. J. Med. Chem. 2025
Arai M., Hanada M., Moriyama H., Ohmoto H., Miyake T., Naka K., Sawa M. Design and synthesis of novel thiazole-derivatives as potent ALK5 inhibitors. Bioorganic Medicinal Chemistry Letters. 2024. 108. 129797
Kazuhito Naka, Akira Ooshima, Takemasa Sakaguchi, Yusuke Sotomaru, Kanae Koike, Naoya Sakamoto, Tomo-o Ishikawa, Seong-Jin Kim, and Masaaki Sawa. SARS-CoV-2 RNA-dependent RNA Polymerase is Linked to Mitochondrial Dysfunction in Mouse Heart. Research Square (プレプリント). 2024
Mino T, Ureshino H, Ueshima T, Kashimoto N, Yamaguchi T, Naka K, Inaba T, Ichinohe T. A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia. Investigational New Drugs. 2023
Tamai M, Fujisawa S, Thu TN, Komatsu C, Kagami K, Kamimoto K, Omachi K, Kasai S, Harama D, Watanabe A, Akahane K, Goi K, Naka K, Kaname T, Teshima T, and Inukai T. Generation of Philadelphia chromosome in human leukemia by DNA breaks on the BCR and ABL1 genes using CRISPR/Cas9 system. Cancer Gene Therapy,. 2022
Yoshihiro Takihara, Yoshinori Ohno, Kyoko Suzuki-Takedachi, Toshiaki Kurogi, Mimoko Santo, Kazuhito Naka, Shin'ichiro Yasunaga. A NEW STRATEGY FOR MANIPULATING EXPRESSION AND ACTIVITY OF GEMININ COULD MAKE IT POSSIBLE TO REGULATE CELL FATES OF HSCS. EXPERIMENTAL HEMATOLOGY. 2015. 43. 9. S97-S97
仲 一仁, 平尾 敦. TGF-β-FOXOシグナルによるCML幹細胞の治療抵抗性機構. 金沢大学十全医学会雑誌 = Journal of the J◆U00FB◆zen Medical Society. 2010. 119. 4. 179-183
Therapeutic agent for chronic myeloid leukemia (出願中,WO/2016/159301 A1, October 6th, 2016)
Composition for inhibiting growth or proliferation of chronic myelogenous leukemia cancer stem cell and a method thereof (出願中,WO/2016/159575 A2, October 6th, 2016)
Pharmaceutical composition for preventing or treating chronic myeloid leukemia and method using the same (出願中,WO/2016/126028 A1, August 11th, 2016)